Compare AstraZeneca plc (AZN) vs Cognizant Technology Solutions Corp (CTSH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Cognizant Technology Solutions Corp — how do they compare? AstraZeneca plc trades at $158.58 (market cap $248.14B), while Cognizant Technology Solutions Corp trades at $57.59 (market cap $26.40B). The key difference: AstraZeneca plc is far larger — about 9.4× Cognizant Technology Solutions Corp's market cap, and Cognizant Technology Solutions Corp pays the higher dividend (2.25%). Which is the better fit depends on your goals.
| AZN | CTSH | |
|---|---|---|
Market Cap | $248.14B | $26.40B |
Sector | Health | Technology |
52-Week High | $209.48 | $86.70 |
52-Week Low | $147.06 | $38.73 |
Enterprise Value | $275.41B | $27.44B |
Dividend Yield | 2.01% | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
CTSH trades at $57.76, down 0.94% on the day, with a bullish technical signal and strong cash flow generation. Recent Q2 2026 earnings missed estimates, but revenue beat, and the company maintains solid profitability with a 10.26% net margin. Analyst consensus is mixed with a $59.92 price target, and the stock shows resilience in financial services growth amid AI investments.
The outlook remains cautiously optimistic with upside potential from AI initiatives and large-deal execution, though risks include client spending caution and competitive pressures. Valuation metrics like a P/E of 12.58 suggest room for growth if earnings momentum improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Cognizant Technology Solutions Corp
Cognizant is a global IT services provider, offering consulting and outsourcing services to some of the world's largest enterprises spanning the financial services, media and communications, healthcare, natural resources, and consumer products industries. Cognizant employs nearly 300,000 people globally, roughly 70% of whom are in India, although the company's headquarters are in Teaneck, New Jersey.
Read more on CTSH →
